Nuvalent, Inc. (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for cancer patients. The company does not yet generate product revenue; it is funded through equity financing and has historically reported net losses as it advances its drug candidates through clinical development. The 10-K filed February 26, 2026 (accession 0001193125-26-07-3317) covers the fiscal year ended December 31, 2025. Nuvalent's pipeline targets kinase-driven oncology indications, with programs designed to address resistance mechanisms seen with existing therapies. The company has no approved products generating commercial revenue as of the filing date, placing it in pre-commercial status. Its capital structure reflects the typical profile of a development-stage biotech: equity-funded with accumulated deficits and no dividend payments.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Arcellx Inc TG Therapeutics Inc Design Therapeutics Inc Editas Medicine Inc Geron Corp IGM Biosciences, Inc. Rocket Pharmaceuticals Inc Kura Oncology Inc Replimune Group Inc